INTRODUCTION:

Polycystic ovary syndrome (PCOS) is a chronic, complex and the most common endocrine disorder observed in women of reproductive age and it also affects the adolescents. Up to 70% of affected women remain undiagnosed or have long delays before the condition is recognised. The prevalence is generally considered to be between 6-20%, depending on the definition and the population studied^1,2. This syndrome is heterogeneous by nature and is characterized by a combination of signs and symptoms of androgen excess and ovarian dysfunction in the absence of other specific diagnoses.4 Women with PCOS often present in their adolescence or early adulthood with symptoms of oligomenorrhoea or hirsutism or infertility³.

Although it was previously considered as a disorder of adult women, recent evidence suggests that PCOS is a lifelong syndrome, manifesting since prenatal age⁴. It is a significant public health issue. The health risks associated with PCOS, however, go far beyond management of these features and likely extend past the reproductive years through and beyond menopause. Women present with diverse features including psychological (anxiety, depression, body image and impaired quality of life), reproductive (irregular menstrual cycles, hirsutism, infertility and pregnancy complications) and significant metabolic features (insulin resistance, metabolic syndrome, prediabetes, type 2 diabetes mellitus and cardiovascular risk factors)⁵. There is also an increased rate of weight gain and prevalence of obesity in PCOS, increasing severity of the condition, causing considerable concern for those affected and mandating attention to healthy lifestyle. PCOS has the potential for serious consequences, including increased risk for the development of endometrial hyperplasia and neoplasia⁶.

In 2003, an overall understanding assemble broke down by hyperandrogenic appearances fuse in skin break out, hirsutism, dyslipidemia, insult opposition, diabetes, rotundity, disease, desolateness and coronary heart contaminations. In view of the Rotterdam Criteria in 2003, polycystic ovaries have as their idea, the proximity of at scarcest one ovary of at least 12 follicles with breadths of 2 - 9mm as well as addition the ovarian gauge > 10ml) 2004. PCOS is clinical or biochemical hyperandrogenism, oligoamenorrhea or amenorrhea, polycystic ovaries and the proximity of (PCOS) by ultrasound⁷. ASRM (American culture of Regenerative Medication) the dig v restriction of different etiologies (characteristic adrenal hyperplasia, hyperprolactinemia, thyroid brokenness, androgendischarging tumors and Cushing disorder). The deep rooted anovulation (CA) with overall power reaching out from 2.2% to 26% in Western countries, 2% to 7.5% in China, 6.3% in Sri Lanka, and 9.13% to 36% in India. Patients with this issue are at higher peril of making insult opposition (IR), weight, dyslipidemia, cardiovascular ailment (CVD), and endometrial carcinoma^8,9. IR and hyperinsulinemia are skilled for the second rate ingrained foundational aggravation¹⁰.

Fig 1. Polycystic ovary syndrome

Characterization of PCOS:

The Rotterdam ESHRE/ASRM—Sponsored PCOS Consensus Workshop Group Fertility and Sterility (2003):

Nearness of 2 out of 3 criteria:

1. Oligovulation or anovulation.

2. Clinical or biochemical indications of hyperandrogenism.

3. Polycystic ovaries on ultrasound.

A. Oligovulation or anovulation of PCOS: Oligovulation is when ovulation happens once in a while or erratically, and as a general rule, is delegated having 8 or less periods in a year. Consistently, a woman ovulates or releases a create egg once per month, around halfway through her cycle¹¹.

B. Clinical and biochemical indications of hyperandrogensim: A Clinical or biochemical indication of hyperandrogemism is: hirsutism, androgenic alopecia, skin break out, acanthuses Nigerians. Hirsutism: It might be a clinical indication of hyperandrogenism. The wisdom of the closeness of hirsutism as an issue relies upon social and ethnic segments. Cause by hair development

· Upper lip

· Chin

· Chest

· Upper back

· Lower back

· Upper midriff

· Upper arm

· Forearm

· Thigh or leg

C. Polycystic ovaries on ultrasound: Ultrasound is the premier extensively used technique for the ultrasound examination of PCO. The sonographic criteria have been thusly balanced and, along these lines, the addition in ovarian volume (>10 cm3) and the proximity of >12 follicles with a broadness of 2 to 9 mm at smallest in one ovary¹². In extension to these criteria, other restorative conditions that can cause steady an ovulation and androgen excess should be restricted, for example,

· Hyperprolactinemia/hyperthyroidism

· Congenital adrenal hyperplasia, traditional and no established structure

· Cushing's disorder; secretary ovarian tumor of adrenal androgens.

Aetiopathogenesis:

The aetiology of PCOS remains unclear and it is likely to be multifactorial. No single aetiologic factor fully accounts for the spectrum of abnormalities in the polycystic ovary syndrome.25 While insulin resistance (IR) and hyperandrogenism are the two key hormonal disturbances that underlies PCOS; obesity, genetic inheritance, lifestyle and environment also contribute¹³. Polycystic ovaries, increased androgen levels owing to defect of the ovarian cells (most likely theca cells), and IR have hereditary components. Environmental factors either congenital or acquired include intrauterine factors such as androgen exposure and prenatal nutrition especially intrauterine growth restriction, whereas a major postnatal factor is acquired obesity influencing the phenotype. Epigenetic reprograming of foetal reproductive tissue following in utero exposure to androgens Review Article Delta Med Col J. Jul 2019; 7(2) 86 Adult Diagnostic Criteria (Rotterdam) Otherwise unexplained alternative phenotypes:

1. Phenotype 1 (Classic PCOS):

a. Clinical and/or biochemical evidence of hyperandrogenism

b. Evidence of oligo-anovulation

c. Ultrasonographic evidence of a polycystic ovary

2. Phenotype 2 (Essential NIH Criteria):

a. Clinical and/or biochemical evidence of hyperandrogenism

b. Evidence of oligo-anovulation

3. Phenotype 3 (Ovulatory PCOS):

a. Clinical and/or biochemical evidence of hyperandrogenism

b. Ultrasonographic evidence of a polycystic ovary

4. Phenotype 4 (Nonhyperandrogenic PCOS):

a. Evidence of oligo-anovulation

b. Ultrasonographic evidence of a polycystic ovary

Adolescent Diagnostic Criteria Otherwise unexplained combination of:

1. Abnormal uterine bleeding pattern a. Abnormal for age or gynecologic age b. Persistent symptoms for 1–2 y

2. Evidence of hyperandrogenism

a. Persistent testosterone elevation above adult norms in a reliable reference laboratory is the best evidence

b. Moderate-severe hirsutism is clinical evidence of hyperandrogenism may trigger hypothalamic-pituitary-ovarian axis of foetus leading to altered folliculogenesis and cause PCOS in later life¹⁴. The complex interactions between these contributing factors generally mimic an autosomal dominant trait with variable penetrance. Ethnic diversity also influences the syndrome’s phenotypic diversity and its prevalence. There is a higher frequency of PCOS in Spanish, Native American and Mexican women.

Different disarranges:

In development to surely understood cardiovascular and metabolic impedances, patients with PCOS show an extended possibility for mental messes and lessened personal satisfaction (QoL) contrasted with sound women. it has been discovered that the prevalence rates of demoralization in PCOS stretch out from 14% to 67%, with a fourfold increasingly noticeable odds of burdensome signs contrasted and age-coordinated control women. The composing showed up an extended power of summed up uneasiness and an addition in unfeeling uneasiness scores in women with PCOS contrasted and control women¹⁵. The Clinic Uneasiness and Misery Scale, the Beck Uneasiness Stock, and the Beck Misery Stock, that evaluates the repeat of mental signs in uneasiness and trouble, independently, that incorporates examination of sentiments, hirsutism influence, weight, menstrual disarranges, and unproductiveness¹⁶.

Cardiovascular hazard:

As point by point by the most coherent social requests women with PCOS show an extended power of great possibility segments for cardiovascular disease. In 2004, an around the globe case-control consider of patients from 52 countries was appropriated. The 95% peoples CVD sway an in the first place myocardial dead tissue in women. The nine factors included smoking, hypertension, dyslipidemia, diabetes, instinctive chubbiness, psychosocial factors, lessened use of weight, psychosocial parts, reduced use of regular items and vegetables, ordinary usage of alcohol, and standard physical activity. The improvement of T2DM and the development of IR to glucose fanaticism and finally T2DM are progressively T2DM occurs inside 2– 3 quite a while and outperform half inside 10 quite a while¹⁷.

Oncology hazard:

Since PCOS is considered as an enduring multisystem and multifaceted mess, the regenerative and metabolic changes portraying the turmoil might be also related with an extended shot of the improvement of malignancies, for example, the endometrial, ovarian, and bosom disease, which perceive potential hormonal as well as metabolic pathogenesis instruments. The potential segments which may propel the beginning of neoplastic ailments in these women, particularly endometrial malignant growth, fuse the steady anovulatory state, coming to fruition in an unopposed estrogen movement, related with hyperandrogenism .The women with PCOS of any age give off an impression of being at an extended danger of endometrial malignant growth. In explicit, the risk of endometrial malignant growth might be undoubtedly higher inside the premenopausal subgroup of women with PCOS, while for the most part the possibility of ovarian and bosom disease was not basically extended¹⁸.

Cosmetic/Local Therapy:

Options available are medical therapy or physical method of removing hairs by threading, waxing, plucking, bleaching, or shaving. The permanent hair-reduction techniques, such as electrolysis, laser thermolysis and photoepilation, are also there in which destruction of hair follicle is done with energy source¹⁹.

Infertility Treatment:

Both the American Task Force and the PCOS Australian Alliance Guidelines recommend clomiphene citrate as first line treatment of anovulatory infertility. The American College of Obstetricians and Gynecologists (ACOG) has recently issued clinical management guidelines that updated the use of letrozole for ovulation induction in women with PCOS. They have advocated letrozole as first-line therapy for ovulation induction because of the increased live birth rate compared with clomiphene citrate²⁰. If clomiphene citrate or letrozole use fails to result in pregnancy, the recommended second-line intervention is either exogenous gonadotropins, in vitro fertilization or laparoscopic ovarian surgery. Laparoscopic techniques that can successfully trigger ovulation include ovarian biopsy and electrocautery, laparoscopic ovarian drilling, transvaginal hydrolaparoscopy, ultrasound guided transvaginal ovarian needle drilling or laparoscopic ovarian multi-needle intervention¹⁷.

Treatment in Adolescents:

Till date no placebo-controlled randomized controlled trials for the treatment of PCOS in adolescents have been conducted. Recommendations suggest individualizing treatment of adolescents with PCOS. 74 Lifestyle modification and weight reduction are considered as part of the first-line treatment, especially in obese adolescents. The mainstay of therapy for adolescents with PCOS is OCPs. However the best OCPs and their appropriate duration of use in adolescents are not well defined. Metformin is also widely used, yet, the necessary treatment period is still indefinite. 6 Early lifestyle modifications and metformin therapy have been associated with promising preventative results²¹.

CONCLUSION:

Polycystic ovary syndrome, though the commonest endocrine pathology, till date research and extensive studies are being carried out as its aetiopathogenesis is still unclear, diagnostic critera are still evolving, management is complex and newer therapeutic options are being explored every day. Often key patient needs are not being met well, and there is gap of knowledge in both patients and health professionals. But what is important to remember and practice is that it is a syndrome more to prevent than to treat. All providers involved in the multidimensional care of women with PCOS should be aware of its long-term health risks to provide appropriate counseling, screening, and management options.

REFERENCES:

1. Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, et al. Polycystic Ovary Syndrome. Nature Reviews Disease Primers. 2016; 2:16057.

2. Gibson-Helm M, Teede H, Dunaif A, Dokras A. Delayed Diagnosis and a Lack of Information Associated with Dissatisfaction in Women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2017; 102:604-12.

3. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound Assessment of the Polycystic Ovary: International Consensus Definitions. Hum Reprod Update. 2003; 9:505-14.

4. Escobar-Morreale HF. Polycystic Ovary Syndrome: Definition, Aetiology, Diagnosis and Treatment. Nature Reviews Endocrinology. 2018; 14:270-84.

5. Cooney LG, Dokras A. Beyond Fertility: Polycystic Ovary Syndrome and Long-Term Health. Fertil Steril. 2018; 110(5):794-809.

6. El Hayek S, Bitar L, Hamdar LH, Mirza FG, Daoud G. Poly Cystic Ovarian Syndrome: An Updated Overview. Front Physiol. 2016; 7:124. doi: 10.3389/fphys.2016.00124.

7. Achard C, Thiers J. Le virilisme pilaire et son association a` l’insuffisance glycolytique (diabe`te des femme a` barbe). Bull Acad Natl Med. 1921; 86:5183.

8. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: A prospective study. J Clin Endocrinol Metab 1998; 83:3078-82.

9. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, et al. A survey of the polycystic ovarysyndrome in the Greek island of Lesbos: Hormonal and metabolic profile. J Clin Endocrinol Metab 1999; 84:4006-11.

10. ovary syndrome in women in China: A large community-based study. Hum Reprod 2013; 28:2562-9

11. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts health across the lifespan. BMC Medicine 2010; 8:4

12. Nicole Gala, RN, is a PCOS and author of “The Everything Fertility Book”.

13. Lujan ME, Chizen DR, Pierson RA. Diagnostic Criteria for Polycystic Ovary Syndrome: Pitfalls and Controversies. J Obstet Gynaecol Can. 2008; 30:671-79

14. Anagnostis P, Tarlatzis BC, Kauffman RP. Polycystic Ovarian Syndrome (PCOS): Long-Term Metabolic Consequences. Metabolism Clinical and Experimental. 2018; 86:33-43.

15. Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update. 2006; 12(6): 673–683.

16. Martins Wde P, Soares GM, Vieira CS, dos Reis RM, de Sá MF, Ferriani RA. Cardiovascular risk markers in polycystic ovary syndrome in women with and without insulin resistance. Rev Bras Ginecol Obstet. 2009; 31(3):111–116

17. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol 2011; 7:219–2311

18. Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and metaanalysis. Hum Reprod Update. 2014; 20(5):748–758

19. Gainder S, Sharma B. Update on Management of Polycystic Ovarian Syndrome for Dermatologists. Indian Dermatol Online J. 2019; 10:97-105.

20. Polycystic Ovary Syndrome. ACOG Practice Bulletin No. 194. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2018; 131:e157-71.

21. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al.; Endocrine Society. Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2013; 98:4565-92.

Received on 25.08.2022 Modified on 26.09.2022

Asian J. Pharm. Res. 2023; 13(1):71-74.

DOI: 10.52711/2231-5691.2023.00014